Articles tagged with Glioblastomas
Researchers have discovered a mechanism to overcome the resistance of human glioblastoma multiforme cells to growth factor inhibitors by blocking inhibitor of apoptosis proteins. Combining drugs targeting IAPs with RTK inhibitors showed enhanced efficacy in inhibiting tumor growth. Additionally, targeting liver CB1 receptors may provid...
Researchers found that RTK inhibitors can be less effective in treating glioblastoma multiforme (GBM) due to cell death inhibition. Combining RTK and IAP inhibitors showed promise in inducing apoptosis in GBM cells, with enhanced efficacy in orthotopic mouse models.
A new vaccine targets glioblastoma multiforme, doubling survival time and more than quadrupling progression-free survival. The vaccine has caused virtually no side effects, making it a promising therapy for this deadly brain tumor.
A new vaccine targeting human cytomegalovirus (CMV) shows promise in delaying the recurrence of deadly brain tumors, glioblastoma multiforme (GBM). The study found that patients receiving the vaccine experienced a significant delay in tumor regrowth, with overall survival extended to over 20 months.
The Novo-TTF device demonstrated significant efficacy in reducing tumor volume and improving outcomes for patients with locally advanced breast cancer. The device's non-invasive technology disrupts cancer cell proliferation, offering a potential alternative to traditional chemotherapy.
Researchers have validated genetic aberrations and identified new targets for GBM treatment. A novel regulatory circuit involving INK4 family genes, p18INK4C and p16INK4A, constrains inappropriate glial cell proliferation and enhances tumorigenicity.
Researchers found that CD95 on glioblastoma cells is activated by CD95L, leading to the production of MMP9, which cuts through tissue layers and allows cancer cells to invade healthy tissue. Blocking this activation may be a new approach to stopping glioblastoma's spread.
Researchers developed gene therapy approach that attracts and 'trains' immune system cells to destroy deadly brain cancer cells, promoting long-term immunity and restoring normal brain function. The therapy shows promise as a potential treatment for glioblastoma multiforme, the most common and deadly type of brain cancer.
Researchers found that STAT3 has tumor-promoting and tumor-suppressing effects depending on the genetic profile of glioblastoma tumors. This discovery highlights the need for effective therapies tailored to individual glioblastoma tumors.
A study published in the Journal of Neurosurgery found that simultaneous implantation of radioactive seeds and chemotherapy wafers following surgery improved patient survival rates for recurrent glioblastoma multiforme (GBM) patients. The median survival was 69 weeks, with nearly a quarter of patients surviving two years.
Researchers developed a three-drug cocktail targeting glioblastoma multiforme tumors, which showed significant benefits in killing cancer cells and sparing healthy brain tissue. The treatment is based on the first-ever documented molecular signature of GBM tumors and may be tested in patients within five years.
A clinical study at Henry Ford Hospital found that Avastin significantly extended the survival of patients with glioblastoma multiforme, with over half living without disease progression for six months. The use of Avastin also showed no new adverse effects.
Researchers found that patients with glioblastoma multiforme treated with radiation and chemotherapy drug temozolomide can live up to four years after diagnosis, compared to three percent of those who received only radiation. The treatment has become the standard for GBM patients worldwide.
A new study found that a combination of bevacizumab (Avastin) and chemotherapy may increase survival time for patients with glioblastoma multiforme, a deadly type of brain tumor. The treatment showed promising results in improving outcomes for patients who have already been diagnosed with the disease.
MIT scientists have discovered a connection between two proteins found in brain tumors that could help treat glioblastoma multiforme (GBM), the most aggressive form of brain cancer. Attacking both EGFRvIII and c-Met simultaneously is more effective than targeting either protein alone, offering new hope for treating this deadly disease.
Researchers found vorinostat's anti-cancer activity in patients with recurrent glioblastoma multiforme, with a 15% patient success rate and improved median overall survival. The study aimed to explore the novel application of vorinostat in targeting brain cancer.
The Novo-TTF device has been shown to disrupt tumor growth by interfering with cell division of cancerous cells, causing them to stop proliferating and die off. In a pilot trial, 10 patients with recurring GBM experienced improved survival rates, with median overall survival doubling compared to historical data.
Researchers have discovered a new class of genetic mutations in the EGFR gene that occur in glioblastoma, a deadly type of brain tumor. These mutations, located in the extracellular domain of the protein, can activate oncogenically EGFR, making them a potential target for cancer therapy.
Mayo Clinic Cancer Center is conducting a clinical study using a vaccine strain of the measles virus to treat recurrent glioblastoma multiforme, a deadly brain tumor. The study has shown promising results in shrinking tumors and prolonging animal survival.
Gliadel Wafer demonstrates long-term survival benefit for patients with high-grade malignant glioma, increasing median survival to 13.9 months from 11.6 months. The treatment also shows a significant reduction in risk of death over the study period, with a 27% lower risk compared to placebo.
Glioblastoma multiforme, the most common adult brain cancer, has a median survival of about one year after diagnosis. Researchers have identified EGFR as a target for therapeutic drugs, offering new hope for patients. The study found that targeting both mutant and normal EGFR can destroy brain cancer cells while sparing healthy ones.
Researchers have discovered a new radiotherapy technique using gadolinium to treat glioblastoma (GBM) with minimal invasiveness. The therapy, called Gadolinium Synchrotron Stereotactic Radiotherapy (GdSSR), targets cancer cells while sparing normal brain tissue, offering a potential cure for this deadly disease.
Researchers identified EGFRvIII and PTEN proteins as key factors in determining tumor response to EGFR inhibitors. These findings suggest that adjusting treatment based on genetic activity could significantly prolong life for glioblastoma patients and prevent unnecessary treatments.
Researchers at UCLA have identified a molecular signature that can predict which patients with glioblastoma, a deadly brain cancer, are likely to respond to drug therapy. The discovery involves the presence of a mutant protein and a tumor suppressor protein called PTEN.
Researchers developed a large brain tumor model and tested a genetically engineered virus delivering two proteins to the brain. The findings show that combined RAdTK and RAdFlt3L gene therapy eliminated glioblastoma multiforme in lab rats, increasing survival rates significantly.
Researchers at Mayo Clinic have developed a new treatment for recurrent glioblastoma multiforme, a form of adult brain cancer with dismal prognosis. The 'smart' drug CCI-779 showed significant response in 36 percent of patients, suggesting potential improvement in treatment outcomes.
A study of 301 patients with glioblastoma multiforme found that the 'SS' variant genotype of hTERT significantly improved survival rates, averaging 25 months compared to 14 months for other genotypes. The research suggests new treatment directions for this aggressive cancer.
Researchers at Cedars-Sinai Medical Center found that a genetically engineered virus delivering the protein hsFlt3L slowed tumor growth and increased immune cell production in laboratory rats with glioblastoma multiforme. The study may lead to a new treatment approach for patients with GBM.
Researchers at Cedars-Sinai Medical Center found that combining an anti-tumor vaccine with chemotherapy significantly extended patient survival to 26 months on average. The treatment, which involves dendritic-cell immunotherapy, was shown to slow tumor growth and increase the effectiveness of chemotherapy.
A phase III study uses IL13-PE38QQR, a hybrid protein that attaches to specific receptors on tumor cells, to target residual GBM brain tumors. The treatment, convection-enhanced delivery, facilitates infusion of the drug into the brain, bypassing the blood-brain barrier.
Cedars-Sinai researchers found that laminin-8 expression is linked to tumor aggressiveness and patient outcomes. High levels of laminin-8 are associated with shorter survival times and increased risk of tumor recurrence.
Scientists at Cedars-Sinai Medical Center used gene array technology to analyze thousands of genes in malignant brain tumor samples. They identified a critical step in the development of glioblastoma multiforme, which may improve patient prognosis and lead to effective therapies.
Researchers at Penn State's College of Medicine have identified a marker for certain types of brain tumors, including glioblastoma multiforme (GBM), which are the most prevalent and difficult-to-manage. The marker, interleukin 13 receptor, is present in over 90% of patients with GBM, making it a valuable diagnostic tool.
Researchers at Thomas Jefferson University are conducting a gene therapy trial for glioblastoma, a form of brain cancer. The trial aims to delay disease progression and improve quality of life for patients, offering a potential cure for the deadliest type of brain tumor.